Concerning authorized drugs, eXinvest Pharmaceuticals signs agreement with pharmaceutical and biotech manufacturers to provide access and distribution services of new drugs on new and promising markets, by managing their commercial launch.
In case of drugs of treatments not yet authorized, we can support companies throughout this delicate transition, in order to strengthen the value and prospects for success of a drug even further, through Regulation, Marketing, Sales, Distribution, Market Access, Price and Refund Definition activities.
Drugs Without Licence
The majority of hospitals in the EU reports severe drugs shortages, and this truly impacts patients’ health and care. In those cases, offering an alternative treatment with drugs without licence available in other Countries is really important. eXinvest Pharmaceuticals can offer this kind of consultancy and support, thanks to its connections with global manufacturers and suppliers, thus ensuring continuous and safe supply of valid alternative treatments.
Sometimes, under certain circumstances, a drug may no longer be available on the market. In this case, eXinvest Pharmaceuticals can intervene by promptly suggesting alternative distribution solutions, so that patients are not obliged to give up their treatment, and can continue to have access to the required drug.
Managed Access Programs
In those Countries and markets where a drug has yet to be launched and distributed, eXinvest Pharmaceuticals can help companies provide their products through managed access programs and Named Patient Supply services. Operators looking for an ethical access to treatments that are not available in a certain market, can resort to our distribution network and our global references.
We can promptly meet the field needs and requirements, by suggesting new or existing treatments, in an ethic and reliable way, and in compliance with the regulations in force in the different Countries.
We offer innovative and consolidated supply, transport, delivery and storage solutions for any kind of treatment. The product is preserved during the entire distribution chain.